PanTheryx Medical Pvt. Ltd.

17 articles about PanTheryx Medical Pvt. Ltd.

• PanTheryx Announces Poster Presentation at 2022 American Dairy Science Association Meeting

  6/22/2022

  PanTheryx , an integrative digestive and immune health company, today announced its poster presentation at the American Dairy Science Association meeting on June 21, 2022 at the Kansas City Convention Center in Missouri.

• New Review Paper Spotlights Bovine Colostrum for Gastrointestinal Health

  6/8/2021

  PanTheryx, the world’s largest colostrum-based nutrition and biotechnology company, announced the publication of a new scientific paper titled, “Colostrum therapy for human gastrointestinal health and disease” in the peer-reviewed journal Nutrients.

• PanTheryx Inc. Acquires TruBiotics® Brand from Bayer HealthCare LLC

  3/1/2021

  PanTheryx Inc. Acquires TruBiotics ® Brand from Bayer HealthCare LLC Acquisition Expands PanTheryx’s Digestive and Immune Health Product Lines for Human Nutrition

• New Bovine Colostrum Scientific Paper Published in Nutrients’ Special Issue

  1/28/2021

  PanTheryx, the world’s largest colostrum-based nutrition and biotechnology company, announced the publication of a new scientific paper titled, “Bovine colostrum: Its constituents and uses” in the peer-reviewed journal Nutrients.

• PanTheryx Acquires Goodgut® and Preliva® Brands from Greenteaspoon Inc.

  10/14/2020

  PanTheryx, the world’s largest colostrum-based nutrition and biotechnology company, announced today it has closed on the purchase of the Goodgut® digestive health brands, including its Preliva® polyphenol prebiotic formula. Goodgut’s plant-based Preliva is designed to help the natural bacteria in the gut flourish which supports the body

• PanTheryx Appoints Tom Feeley as Chief Financial Officer

  7/1/2020

  PanTheryx, the world’s largest colostrum-based nutrition and biotechnology company, announced today the appointment of Tom Feeley to the position of Chief Financial Officer (CFO). Mr. Feeley began his role with PanTheryx on June 22 and reports to President and Chief Executive Officer Wes Parris. Mr. Feeley will be responsible for the development and execution of PanTheryx’s financial strategy including all Finance, Account

• Holger Liepmann and Peter Erickson Join PanTheryx Board of Directors

  4/10/2020

  Liepmann and Erickson add invaluable industry expertise to the Board with more than 60 combined years of nutrition and food science experience

• PanTheryx Announces New CEO and Chairman

  1/13/2020

  PanTheryx announced today that CEO Mark Braman is retiring and nutrition industry veteran, Wes Parris, formerly of I-Health, Inc., will replace Braman as CEO effective immediately.

• PanTheryx Bovine Colostrum Recognized as GRAS

  12/9/2019

  Independent expert panel recognizes gut and immune supporting ingredient from leading biotechnology company as Generally Recognized as Safe (GRAS)

• PanTheryx Announces Exclusive Multimillion Dollar Agreement between APS BioGroup and VitaDairy in Pediatric and Maternal Immunonutrition

  11/20/2019

  World leader in bovine colostrum manufacturing and research launches new deal with Vietnamese nutritional dairy company, becoming the exclusive colostrum supplier for its immunonutrition products

• PanTheryx Announces Dr. Mehmet Oz to Join its Board of Directors

  9/13/2019

  PanTheryx, a biotechnology company, today announced that it has appointed Dr. Mehmet C. Oz, MD, surgeon and talk show host “Dr. Oz” from The Dr. Oz Show, to the company’s board of directors.

• PanTheryx Aims to End Diarrheal Disease in Cambodia

  7/11/2019

  Company launches new efforts through its Equity of Access Initiative to reduce the burden of pediatric infectious diarrhea on the poorest and hardest to reach children in Cambodia.

• Breakthrough Diarrhea Product To Help Improve the Health of Millions in Cambodia

  7/11/2019

  PanTheryx partners with Zuellig Pharma to launch DiaResQ in Cambodia.

• PanTheryx Announces $50 Million Financing, Accelerates Development of its Novel Biologics and Medical Foods Candidates

  6/26/2019

  PanTheryx, a biotechnology company focused on addressing serious GI related health conditions, announced today that it has completed $50 million in new financing with Perceptive Advisors.

• Rajiv Shah and Tom Bumol Join PanTheryx Board of Directors as Biotech Expands Pipeline Candidates with Substantial R&D Investment

  4/2/2019

  PanTheryx, a biotechnology company focused on addressing serious GI related health conditions, announced today the appointment of Dr. Rajiv Shah, MD, president of the Rockefeller Foundation, and Dr. Tom Bumol, PhD, executive director of the Allen Institute for Immunology, to its board of directors.

• PanTheryx Presents Positive Results from Two New DiaResQ Studies at its 2019 International Scientific Symposium

  3/2/2019

  New clinical data and case studies highlight the use of DiaResQ in a range of real world settings, from hospitals to disaster relief, in its first annual scientific meeting

• PanTheryx Medical Pvt. Ltd. Grabs $53 Million Financing Deal with Pegasus Capital Advisors

  3/30/2016